On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50. This comes after the company released promising results from the Phase 2 TRANQUILITY trial of Pacibekitug.
A scientist in a white lab coat working at a bench with biopharmaceutical equipment.
Analyst Chen noted the results from the Phase 2 TRANQUILITY trial showed a significant reduction in high-sensitivity C-reactive protein (hs-CRP) levels in patients with kidney disease. The candidate also achieved a rapid and durable reduction in hs-CRP compared to the existing Ziltivekimab. Chen believes this can increase the potential market share of Tourmaline Bio, Inc.’s Pacibekitug.
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company developing treatments for life-altering immune and inflammatory diseases. Pacibekitug (TOUR006), is the company’s lead product. It is a fully human monoclonal antibody designed to have a long half-life, high binding affinity to IL-6, and low immunogenicity.
READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.
